دورية أكاديمية
أعرض في EDS

Advances in lung bioengineering: Where we are, where we need to go, and how to get there.

التفاصيل البيبلوغرافية
العنوان: Advances in lung bioengineering: Where we are, where we need to go, and how to get there.
المؤلفون: Hsiung T; Department of Cardiothoracic Surgery, NYU Langone Health, New York, NY, United States., James L; Department of Cardiothoracic Surgery, NYU Langone Health, New York, NY, United States., Chang SH; Department of Cardiothoracic Surgery, NYU Langone Health, New York, NY, United States.; Department of Cardiothoracic Surgery, NYU Transplant Institute, NYU Langone Health, New York, NY, United States., Geraci TC; Department of Cardiothoracic Surgery, NYU Langone Health, New York, NY, United States.; Department of Cardiothoracic Surgery, NYU Transplant Institute, NYU Langone Health, New York, NY, United States., Angel LF; Department of Cardiothoracic Surgery, NYU Langone Health, New York, NY, United States.; Department of Cardiothoracic Surgery, NYU Transplant Institute, NYU Langone Health, New York, NY, United States., Chan JCY; Department of Cardiothoracic Surgery, NYU Langone Health, New York, NY, United States.; Department of Cardiothoracic Surgery, NYU Transplant Institute, NYU Langone Health, New York, NY, United States.
المصدر: Frontiers in transplantation [Front Transplant] 2023 Apr 17; Vol. 2, pp. 1147595. Date of Electronic Publication: 2023 Apr 17 (Print Publication: 2023).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Frontiers Country of Publication: Switzerland NLM ID: 9918573988006676 Publication Model: eCollection Cited Medium: Internet ISSN: 2813-2440 (Electronic) Linking ISSN: 28132440 NLM ISO Abbreviation: Front Transplant Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Lausanne : Frontiers, 2022-
مستخلص: Lung transplantation is the only potentially curative treatment for end-stage lung failure and successfully improves both long-term survival and quality of life. However, lung transplantation is limited by the shortage of suitable donor lungs. This discrepancy in organ supply and demand has prompted researchers to seek alternative therapies for end-stage lung failure. Tissue engineering (bioengineering) organs has become an attractive and promising avenue of research, allowing for the customized production of organs on demand, with potentially perfect biocompatibility. While breakthroughs in tissue engineering have shown feasibility in practice, they have also uncovered challenges in solid organ applications due to the need not only for structural support, but also vascular membrane integrity and gas exchange. This requires a complex engineered interaction of multiple cell types in precise anatomical locations. In this article, we discuss the process of creating bioengineered lungs and the challenges inherent therein. We summarize the relevant literature for selecting appropriate lung scaffolds, creating decellularization protocols, and using bioreactors. The development of completely artificial lung substitutes will also be reviewed. Lastly, we describe the state of current research, as well as future studies required for bioengineered lungs to become a realistic therapeutic modality for end-stage lung disease. Applications of bioengineering may allow for earlier intervention in end-stage lung disease and have the potential to not only halt organ failure, but also significantly reverse disease progression.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(© 2023 Hsiung, James, Chang, Geraci, Angel and Chan.)
References: Biomaterials. 2015 Feb;40:72-9. (PMID: 25433603)
J Korean Med Sci. 2022 Oct 24;37(41):e294. (PMID: 36281485)
Biomaterials. 2017 Sep;140:212-219. (PMID: 28662401)
N Engl J Med. 2001 Feb 15;344(7):532-3. (PMID: 11221621)
Adv Healthc Mater. 2020 Aug;9(15):e1901648. (PMID: 32352649)
Ann Surg. 2018 Mar;267(3):590-598. (PMID: 28085694)
Lancet. 2006 Apr 15;367(9518):1241-6. (PMID: 16631879)
Tissue Eng Part A. 2010 May;16(5):1515-26. (PMID: 20001250)
Sci Rep. 2017 Oct 12;7(1):13082. (PMID: 29026127)
Semin Thorac Cardiovasc Surg. 2021 Spring;33(1):263-271. (PMID: 32348880)
Biomaterials. 2016 Mar;83:283-93. (PMID: 26790147)
J Thorac Dis. 2017 Jan;9(1):22-29. (PMID: 28203403)
Biomaterials. 2014 Mar;35(10):3281-97. (PMID: 24461327)
Sci Adv. 2017 Aug 30;3(8):e1700521. (PMID: 28875163)
Biomaterials. 2012 Feb;33(6):1771-81. (PMID: 22137126)
Transplantation. 2022 Aug 1;106(8):1507-1509. (PMID: 35881517)
Science. 2010 Jul 30;329(5991):538-41. (PMID: 20576850)
Tissue Eng Part B Rev. 2017 Aug;23(4):412-419. (PMID: 28068870)
Ann Thorac Surg. 2014 Nov;98(5):1721-9; discussion 1729. (PMID: 25149047)
Biomaterials. 2020 Nov;258:120310. (PMID: 32823019)
N Engl J Med. 2011 Apr 14;364(15):1431-40. (PMID: 21488765)
J Thorac Cardiovasc Surg. 2020 Jun;159(6):2525-2537.e23. (PMID: 31859073)
Ann Thorac Surg. 2011 Sep;92(3):998-1005; discussion 1005-6. (PMID: 21871290)
Eur Respir J. 2018 Jul 27;52(1):. (PMID: 29903859)
Nat Protoc. 2014 Sep;9(9):2164-79. (PMID: 25122525)
Sci Rep. 2017 Aug 16;7(1):8447. (PMID: 28814761)
J Thorac Cardiovasc Surg. 2020 Apr;159(4):1640-1653.e18. (PMID: 31761338)
Acta Biomater. 2016 Jul 1;38:82-93. (PMID: 27134015)
J Biomater Appl. 2006 Oct;21(2):109-18. (PMID: 16443629)
Biomaterials. 2014 Mar;35(9):2664-79. (PMID: 24411675)
Tissue Eng. 2006 Apr;12(4):717-28. (PMID: 16674286)
J Clin Transl Res. 2015 Jul 19;1(1):48-56. (PMID: 30873444)
IEEE Trans Biomed Eng. 2014 May;61(5):1482-96. (PMID: 24691527)
Proc Am Thorac Soc. 2008 Sep 15;5(7):763-6. (PMID: 18757314)
Nat Med. 2010 Jul;16(7):814-20. (PMID: 20543851)
Nat Med. 2010 Aug;16(8):927-33. (PMID: 20628374)
Tissue Eng Part A. 2012 Dec;18(23-24):2437-52. (PMID: 22764775)
Front Bioeng Biotechnol. 2021 Nov 24;9:773511. (PMID: 34900964)
J Heart Lung Transplant. 2008 Dec;27(12):1319-25. (PMID: 19059112)
Tissue Eng. 2006 May;12(5):1213-25. (PMID: 16771635)
Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13793-8. (PMID: 22869753)
Tissue Eng Part C Methods. 2016 Aug;22(8):725-39. (PMID: 27310581)
Nat Biotechnol. 2015 Oct;33(10):1097-102. (PMID: 26368048)
Sci Transl Med. 2018 Aug 1;10(452):. (PMID: 30068570)
Curr Stem Cell Res Ther. 2017;12(3):233-246. (PMID: 27593448)
Surg Today. 2020 Jul;50(7):633-643. (PMID: 32363425)
Tissue Eng Part A. 2013 Jul;19(13-14):1527-33. (PMID: 23252967)
Methods Mol Biol. 2017;1627:253-283. (PMID: 28836208)
Biofabrication. 2020 Mar 27;12(2):025031. (PMID: 32084662)
Science. 2019 May 3;364(6439):458-464. (PMID: 31048486)
Tissue Eng Part C Methods. 2010 Feb;16(1):157-66. (PMID: 19586367)
Nature. 2020 Nov;587(7834):466-471. (PMID: 33116313)
PLoS One. 2021 Jul 1;16(7):e0253520. (PMID: 34197496)
Biomacromolecules. 2013 Jan 14;14(1):38-47. (PMID: 23134349)
PLoS One. 2016 Mar 08;11(3):e0150966. (PMID: 26954258)
ASAIO J. 2019 Jul;65(5):516-521. (PMID: 30044239)
Nat Biotechnol. 2014 Jan;32(1):84-91. (PMID: 24291815)
Biomed Res Int. 2017;2017:9831534. (PMID: 28540307)
Biomaterials. 2016 Sep;102:20-42. (PMID: 27318933)
J Surg Res. 2009 Mar;152(1):135-9. (PMID: 18619621)
J Clin Invest. 2013 Nov;123(11):4950-62. (PMID: 24135142)
Lancet. 2008 Dec 13;372(9655):2023-30. (PMID: 19022496)
Front Bioeng Biotechnol. 2020 Aug 06;8:776. (PMID: 32850697)
Tissue Eng Part C Methods. 2012 Aug;18(8):632-46. (PMID: 22404373)
Front Bioeng Biotechnol. 2021 Oct 19;9:756755. (PMID: 34746108)
Science. 1993 May 14;260(5110):920-6. (PMID: 8493529)
Tissue Eng Part C Methods. 2019 Aug;25(8):459-471. (PMID: 31317819)
Biomaterials. 2016 Sep;102:220-30. (PMID: 27344365)
Semin Thorac Cardiovasc Surg. 2022 Summer;34(2):752-759. (PMID: 33713829)
Front Bioeng Biotechnol. 2020 Apr 15;8:269. (PMID: 32351946)
Methods. 2015 Aug;84:25-34. (PMID: 25791470)
Cells. 2021 Oct 10;10(10):. (PMID: 34685693)
Front Pharmacol. 2019 Feb 08;10:74. (PMID: 30800069)
Am J Transplant. 2022 Mar;22 Suppl 2:438-518. (PMID: 35266615)
Sci Rep. 2015 Jan 22;5:7974. (PMID: 25609567)
Sci Rep. 2015 Jun 01;5:10756. (PMID: 26030843)
Appl Sci (Basel). 2019 Apr;9(7):. (PMID: 31890320)
Front Bioeng Biotechnol. 2022 May 09;10:846632. (PMID: 35646864)
Am J Transplant. 2018 Jun;18(6):1351-1359. (PMID: 29338127)
فهرسة مساهمة: Keywords: bioreactor; ex vivo lung perfusion; extracorporeal membrane oxygenation; lung transplant; tissue engineering; tissue scaffolds
تواريخ الأحداث: Date Created: 20240712 Latest Revision: 20240714
رمز التحديث: 20240714
مُعرف محوري في PubMed: PMC11235378
DOI: 10.3389/frtra.2023.1147595
PMID: 38993882
قاعدة البيانات: MEDLINE
الوصف
تدمد:2813-2440
DOI:10.3389/frtra.2023.1147595